Translation and Validation of the Turkish Version of JSE-HPS (JSE-HPS)

December 13, 2020 updated by: Alper Tuğral, Izmir Bakircay University

The Reliability, Validity and Cross-Cultural Adaptation of the Turkish Version of Jefferson Scale of Empathy For Health Professional Students

Empathy, which can be briefly defined as understanding and feeling of one's thoughts upon experiences. It has been gaining importance in health care. A great majority of the literature has been focusing on the aspect of physician and health care provider yet recently establishing or measuring empathy has been performed with the undergraduate students. Since empathy and its related dimensions are important to integrate a better skill to provide in health care, measuring empathy gained attention. However, there might be lacking some tools which assess empathy directly such as the Empathic Tendency Scale and the Empathic Skill Scale in the Turkish language, yet these were discussed as cannot be quite modifiable to some specific sub-groups such as health sciences students. Thus, this study is aimed to study for the reliability, validity, and cross-cultural adaptation of the Turkish version of the Jefferson Scale of Empathy for undergraduate health care students.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The research has been aimed at studying translation, validation, a cross-cultural adaptation of the Turkish version of the Jefferson Scale of Empathy for Health Professional Students (JSE-HPS).

Study Setting:

This research was planned as a descriptive study. The research is planning to be performed between May 2020 and October 2020. The students who are currently studying in the Faculty of Health Sciences will be asked to participate in this study. Since ethical board approval was taken in February 2020 and study was planned to start in March or April 2020. However, due to the Covid-19 pandemic, the research in which test and re-test protocols should be performed by students was re-planned by doing these protocols via internet-based forms. Before the study, all participating students were informed about this study. To achieve their consent in regard to participate in this study, a "tick-box" was placed prior to the questionnaire in which whether they accept that participating in this study voluntarily. The primary target for sample size was set as 300 students.

Measurement and Method:

The descriptive data will be gathered by using the Jefferson Scale of Empathy for health professional students (JSE-HPS), the Turkish version of Empathic tendency scale (ETS), and sociodemographic form in which age, gender, and other information will be requested to fill out.

JSE-HPS:

JSE-HPS was originally developed by Jefferson University. It consists of 20 items each scored according to the seven-point Likert type scale in which 1 means "Strongly Disagree" while 7 means "Strongly agree". The minimum and maximum scores range from 20 to 140. Higher scores indicate a better empathic aspect or vice versa.

Empathic Tendency Scale (ETS):

ETS was originally developed in the Turkish language in 1988. Turkish validation and reliability of ETS were also conducted and found to reliable according to the Cronbach's alpha value is 0.82. ETS consists of 20 items each scored according to the five-point Likert type scale in which 1 equals "Completely contradictory" while 5 means "Completely proper". Each item is related to some ideas which are quite common in daily life. 20 and 100 are minimum and maximum scores, respectively. Higher scores indicate a better empathic aspect.

Translation and Cross-cultural Adaptation Process:

The permission was granted from the copyright Holder of JSE-HPS in order to study the reliability, validity, and adaptation of the Turkish version of JSE-HPS. The cultural adaptation was performed according to the protocol explained by Beaton et al. Steps and a detailed explanation of this protocol can be found in the literature. Briefly, an expert committee consists of study researchers separately translated the original version of the JSE-HPS into Turkish. The final version of the Turkish translated JSE-HPS was created according to the separately translated ones. This final version was re-translated to English by a native English speaker who is also capable to talk Turkish language. The expert committee eventually made a final version to which can be applicable to the participants.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
167

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • İzmir, Turkey, 35565
        • İzmir Bakırçay University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Being currently studying at the Faculty of Health Sciences
  • Able to read, write and understand the Turkish language
  • Having no mental medical conditions
  • Being a volunteer to participate in this study

Exclusion Criteria:

  • Inability to read, write and understand Turkish language
  • Not volunteer to participate in this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Health Professional Students
A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
Other: Questionnaire
A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Jefferson Scale of Empathy Health Professional Students Questionnaire
Time Frame: Baseline
The Turkish version of Jefferson Scale of Empathy Health Professional Students (JSE-HPS) will be applied to participants. The minimum and maximum scores for JSE-HPS can be reached to 20 and 140, respectively. The more the higher scores indicate more empathic aspect or vice versa.
Baseline
Jefferson Scale of Empathy Health Professional Students Questionnaire
Time Frame: 1 week after baseline
The Turkish version of Jefferson Scale of Empathy Health Professional Students (JSE-HPS) will be applied to participants. The minimum and maximum scores for JSE-HPS can be reached to 20 and 140, respectively. The more the higher scores indicate more empathic aspect or vice versa.
1 week after baseline
Empathic Tendency Scale (ETS) Questionnaire
Time Frame: Baseline
The Turkish version of Empathic Tendency Scale (ETS) Questionnaire will be applied to participants. The minimum and maximum scores can be taken from the tool are 20 and 100, respectively in which higher scores indicate better empathic attitude or vice versa.
Baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Demographic Data Form
Time Frame: Baseline
Basic Form gathers some information related participants' age, gender etc.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Izmir Bakircay University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Elif Günay İsmailoğlu, PhD, Izmir Bakircay University
  • Principal Investigator: Kadirhan Özdemir, PhD, Izmir Bakircay University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 15, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 20, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 10, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 3, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 5, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 9, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 16, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 13, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BakircayU07/07022020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Surveys and Questionnaires

Clinical Trials on Questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings